Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Determine the Safety, Pharmacokinetics, Food, and Fecal Microbiome Effects of ACX-362E Administered Orally to Healthy Subjects

Next Previous
Trial Profile

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Determine the Safety, Pharmacokinetics, Food, and Fecal Microbiome Effects of ACX-362E Administered Orally to Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibezapolstat (Primary) ; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Acurx Pharmaceuticals

Most Recent Events

  • 24 Sep 2024 According to an Acurx Pharmaceuticals media release, results from this study were presented at the premier International C. difficile Symposium (ICDS) held in Bled, Slovenia on September 17-19, 2024, in a presentation delivered by Dr. Wiep Klaas Smits, PhD, Associate Professor, Leiden University Medical Center (LUMC).
  • 26 Oct 2022 According to an Acurx Pharmaceuticals media release, data from this study was presented at the Infectious Disease Society of America (IDSA) IDWeek 2022 Conference.
  • 17 Oct 2022 According to an Acurx Pharmaceuticals media release, data from this study will be presented at the Infectious Disease Society of America (IDSA) IDWeek 2022 Conference

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top